NASDAQ: AEMDAethlon Medical Inc Stock
$0.34-0.02 (-5.56%)
Updated Jun 8, 2023
AEMD Price
$0.34
Fair Value Price
$1.11
Market Cap
$7.90M
52 Week Low
$0.23
52 Week High
$2.46
P/E
-0.46x
P/B
0.46x
P/S
481.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.12k
Earnings
-$13.35M
Gross Margin
100%
Operating Margin
-101,768.29%
Profit Margin
-101,768.3%
Debt to Equity
0.2
Operating Cash Flow
-$11M
Beta
0.47
Next Earnings
Jun 26, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AEMD Overview
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AEMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AEMD ($0.34) is undervalued by 68.92% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AEMD ($0.34) is significantly undervalued by 68.92% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AEMD due diligence checks available for Premium users.
Be the first to know about important AEMD news, forecast changes, insider trades & much more!
AEMD News
Valuation
AEMD fair value
Fair Value of AEMD stock based on Discounted Cash Flow (DCF)
Price
$0.34
Fair Value
$1.11
Undervalued by
69.28%
AEMD ($0.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AEMD ($0.34) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AEMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.46x
Industry
788.88x
Market
52.58x
AEMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
3.92x
AEMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AEMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.8M
Profit Margin
0%
AEMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AEMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.7M
Liabilities
$3.4M
Debt to equity
0.2
AEMD's short-term assets ($18.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEMD's short-term assets ($18.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AEMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$151.5k
Financing
-$1.9k
AEMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AEMD vs Medical Device Stocks
Aethlon Medical Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.